Hidden side effects behind the use of LARTRUVO

Olaratumab, trade name: LARTRUVO, is a humanized monoclonal antibody mainly used to treat advanced soft tissue sarcoma. Although LARTRUVO has been clinically shown to be effective against certain cancers, it may also cause a series of side effects that require close monitoring by patients and medical personnel.

Common side effects:

Nausea and Vomiting:LARTRUVOOne of the most common side effects of treatment may occur after first use.

Fatigue: Many patients experience persistent fatigue, which affects daily life and work.

Injection site reactions: include redness, pain, swelling, and sometimes allergic reactions.

Decreased white blood cells: May lead to decreased immune system function and increased risk of infection.

Abnormal liver function: Some patients may experience elevated liver enzymes, and liver function indicators need to be checked regularly.

Anemia: Due to a decrease in red blood cells, anemia may occur, leading to symptoms such as dizziness and fatigue.

Serious side effects:

Allergic Reaction: A very small number of patients may experience allergic reactions, such as shortness of breath, throat swelling, rash, etc., and require immediate medical attention.

Heart Problems:LARTRUVO may have adverse effects on the heart, especially when used in combination with chemotherapy drugs, which may cause a decrease in heart function.

Thrombocytopenia: affects coagulation function and increases the risk of bleeding.

Kidney damage: The function of the kidneys may be affected, manifesting as symptoms such as decreased urine output or edema.

When usingLARTRUVO, it is recommended to have regular blood tests, liver and kidney function tests, and heart function assessments to ensure that potential side effects are detected in a timely manner.

Reference materials:https://www.drugs.com/cdi/olaratumab.html